Quick answer: to convert a retatrutide dose from mg to syringe units, divide the vial size by the water you add to get the concentration, then divide the dose by the concentration. On a U-100 insulin syringe, 1 mL = 100 units. Example: a 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL, so 2 mg = 0.4 mL = 40 units.

Retatrutide (LY3437943) is an investigational once-weekly triple agonist of the GLP-1, GIP and glucagon receptors. It is not approved by any regulatory agency, and this page is a research reference that explains the math and the published trial data. It is not dosing advice. Use the calculator below for any vial size.

Retatrutide Dosage Calculator

Enter the vial size, the bacteriostatic water you add and the dose to see the volume and syringe units. Works for any vial size.

Concentration–
Volume to draw–
Syringe units (U-100)–
Doses per vial–

Math only: units = dose ÷ (vial mg ÷ water mL) × 100 on a U-100 insulin syringe. This calculator converts amounts and does not recommend a dose. Retatrutide is an investigational compound and is not approved by any regulatory agency.

Retatrutide Units Chart by Vial Size

The table shows U-100 syringe units for common vial sizes, each mixed with 2 mL of bacteriostatic water. If you use a different amount of water, use the calculator above.
Dose 5 mg vial (2.5 mg/mL) 10 mg vial (5 mg/mL) 20 mg vial (10 mg/mL) 40 mg vial (20 mg/mL)
1 mg 40 units 20 units 10 units 5 units
2 mg 80 units 40 units 20 units 10 units
4 mg 160 units* 80 units 40 units 20 units
8 mg 320 units* 160 units* 80 units 40 units
12 mg 480 units* 240 units* 120 units* 60 units
*More than one 1 mL (100-unit) syringe. A more concentrated mix (less water) lowers the volume. For the specific 10 mg vial reference, see the GLP-3R 10 mg vial protocol.

Retatrutide Dosing Chart (Clinical Trial Doses)

The main published dose data come from the phase 2 obesity trial (Jastreboff et al., NEJM 2023). Participants received retatrutide once weekly for 48 weeks. The higher-dose groups started at 2 mg or 4 mg and were increased stepwise to their target dose.
Target weekly dose Escalation steps Mean body-weight change at 48 weeks
1 mg 1 mg throughout −8.7%
4 mg 2 → 4 mg, or 4 mg throughout −17.1% (both groups combined)
8 mg 2 → 4 → 8 mg, or 4 → 8 mg −22.8% (both groups combined)
12 mg 2 → 4 → 8 → 12 mg −24.2%
Placebo – −2.1%
In this trial, gastrointestinal side effects were partly reduced by starting at the lower dose (2 mg rather than 4 mg). Phase 3 trials (the TRIUMPH program) are testing doses up to 12 mg weekly.
Retatrutide dosage calculator and dosing chart
Retatrutide dosage calculator and dosing chart

How to Calculate Retatrutide Dosage by Hand

Research peptides usually come as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water. The calculation has four steps.

Step 1: Note the vial strength

Example: a 10 mg vial.

Step 2: Note the water added

Example: 2 mL of bacteriostatic water.

Step 3: Work out the concentration

10 mg ÷ 2 mL = 5 mg per mL

Step 4: Convert the dose to volume and units

For a 2 mg amount: 2 mg ÷ 5 mg/mL = 0.4 mL. On a U-100 insulin syringe, 0.4 mL × 100 = 40 units. The same formula works for any vial: units = dose (mg) ÷ (vial mg ÷ water mL) × 100. For other peptides, use the general peptide calculator.

Retatrutide Half-Life

In the phase 1b trial (Urva et al., The Lancet 2022), retatrutide’s half-life was about 6 days, and its pharmacokinetics were dose-proportional. That half-life is why the trials use once-weekly dosing. As a simplified estimate after a single dose, about half remains after ~6 days, a quarter after ~12 days and about 12% after ~18 days. With repeated weekly doses, levels build up to a steady state over roughly 4–5 half-lives (about a month).

How Retatrutide Works

Retatrutide activates three receptors at once:
  1. GLP-1 receptor: appetite and insulin secretion
  2. GIP receptor: glucose metabolism and fat regulation
  3. Glucagon receptor: energy expenditure and fat breakdown
The glucagon component is what sets it apart from GLP-1-only and GLP-1/GIP compounds. In research circles, retatrutide is often nicknamed “GLP-3”. See the GLP-3 peptide guide for background, and the cagrilintide research guide for a related amylin-pathway compound.

Side Effects and Safety

In the phase 2 trial, the most common side effects were gastrointestinal: nausea, vomiting, diarrhea and reduced appetite. These were dose-related, mostly mild to moderate, and most common during dose escalation. Heart rate also rose in a dose-dependent way, peaking at 24 weeks and then declining. Other reported reactions include fatigue, injection-site irritation and dizziness. Anyone with severe symptoms should seek medical attention. Retatrutide is investigational. Lilly states that it is not approved by any regulatory agency and should not be taken outside a Lilly-sponsored clinical trial. For research use, compounds should come with third-party testing and a certificate of analysis, and should be stored correctly.

Frequently Asked Questions

How do I convert retatrutide mg to units?

Divide the vial mg by the mL of water to get the concentration, divide the dose by the concentration to get mL, then multiply by 100 for U-100 syringe units. Example: 10 mg in 2 mL = 5 mg/mL, so 2 mg = 0.4 mL = 40 units.

How many units is 2 mg of retatrutide?

It depends on the concentration: 80 units at 2.5 mg/mL (5 mg vial + 2 mL), 40 units at 5 mg/mL (10 mg vial + 2 mL), 20 units at 10 mg/mL (20 mg vial + 2 mL) and 10 units at 20 mg/mL (40 mg vial + 2 mL).

What doses of retatrutide were studied in clinical trials?

The phase 2 obesity trial tested 1 mg, 4 mg, 8 mg and 12 mg once weekly. The higher doses were reached stepwise, for example 2 → 4 → 8 → 12 mg for the 12 mg group. The 12 mg group lost an average of 24.2% of body weight at 48 weeks.

How often is retatrutide dosed in studies?

Once weekly. Its half-life of about 6 days supports a weekly schedule.

Is retatrutide approved?

No. As of October 2026, retatrutide is not approved by any regulatory agency. Lilly is studying it in the phase 3 TRIUMPH program and says it should not be used outside its clinical trials.

Is retatrutide the same as “GLP-3”?

“GLP-3” is an informal nickname for retatrutide, based on its triple-receptor action. It is not an official name. See the GLP-3 peptide guide.

References

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972 Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5 Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013 ClinicalTrials.gov. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760). clinicaltrials.gov/study/NCT04881760 Eli Lilly and Company. What to know about retatrutide. lilly.com